Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
@prefix fhir: <http://hl7.org/fhir/> . @prefix owl: <http://www.w3.org/2002/07/owl#> . @prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> . @prefix xsd: <http://www.w3.org/2001/XMLSchema#> . # - resource ------------------------------------------------------------------- a fhir:Bundle ; fhir:nodeRole fhir:treeRoot ; fhir:id [ fhir:v "bundlepackageleaflet-en-9e5179bf4e803289b510a39f498792d0"] ; # fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"^^xsd:anyURI ; fhir:link <http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi> ] ) ] ; # fhir:language [ fhir:v "en"] ; # fhir:identifier [ fhir:system [ fhir:v "http://ema.europa.eu/identifier"^^xsd:anyURI ] ; fhir:value [ fhir:v "None" ] ] ; # fhir:type [ fhir:v "document"] ; # fhir:timestamp [ fhir:v "2023-06-27T10:09:22Z"^^xsd:dateTime] ; # fhir:entry ( [ fhir:fullUrl [ fhir:v "Composition/composition-en-9e5179bf4e803289b510a39f498792d0"^^xsd:anyURI ] ; ( fhir:resource <Composition/composition-en-9e5179bf4e803289b510a39f498792d0> ) ] [ fhir:fullUrl [ fhir:v "MedicinalProductDefinition/mp9e5179bf4e803289b510a39f498792d0"^^xsd:anyURI ] ; ( fhir:resource <MedicinalProductDefinition/mp9e5179bf4e803289b510a39f498792d0> ) ] ) . # <Composition/composition-en-9e5179bf4e803289b510a39f498792d0> a fhir:Composition ; fhir:id [ fhir:v "composition-en-9e5179bf4e803289b510a39f498792d0"] ; # fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"^^xsd:anyURI ; fhir:link <http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi> ] ) ] ; # fhir:language [ fhir:v "en"] ; # fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-9e5179bf4e803289b510a39f498792d0\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-9e5179bf4e803289b510a39f498792d0</b></p><a name=\"composition-en-9e5179bf4e803289b510a39f498792d0\"> </a><a name=\"hccomposition-en-9e5179bf4e803289b510a39f498792d0\"> </a><a name=\"composition-en-9e5179bf4e803289b510a39f498792d0-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/15/1061/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - genvoya</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>" ] ; # fhir:identifier ( [ fhir:system [ fhir:v "http://ema.europa.eu/identifier"^^xsd:anyURI ] ; fhir:value [ fhir:v "EU/1/15/1061/001" ] ] ) ; # fhir:status [ fhir:v "final"] ; # fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "Package Leaflet" ] ] ; # fhir:category ( [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"^^xsd:anyURI ] ; fhir:code [ fhir:v "R" ] ; fhir:display [ fhir:v "Raw" ] ] ) ] ) ; # fhir:subject ( [ fhir:reference [ fhir:v "MedicinalProductDefinition/mp9e5179bf4e803289b510a39f498792d0" ] ] ) ; # fhir:date [ fhir:v "2022-02-16T13:28:17Z"^^xsd:dateTime] ; # fhir:author ( [ fhir:reference [ fhir:v "Organization/mah-ema" ] ] ) ; # fhir:title [ fhir:v "TEST PURPOSES ONLY - genvoya"] ; # fhir:attester ( [ fhir:mode [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/composition-attestation-mode"^^xsd:anyURI ] ; fhir:code [ fhir:v "official" ] ] ) ] ; fhir:time [ fhir:v "2022-02-16T13:28:17Z"^^xsd:dateTime ] ] ) ; # fhir:section ( [ fhir:title [ fhir:v "B. Package Leaflet" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "B. Package Leaflet" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>" ] ; fhir:emptyReason [ ( fhir:coding [ fhir:system [ fhir:v "http://terminology.hl7.org/CodeSystem/list-empty-reason"^^xsd:anyURI ] ; fhir:code [ fhir:v "unavailable" ] ] ) ] ; ( fhir:section [ fhir:title [ fhir:v "Package leaflet: Information for the user" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "Package leaflet: Information for the user" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>If Genvoya has been prescribed for your child, please note that all the information in this leaflet is addressed to your child (in this case please read your child instead of you ).</p></div>" ] ] [ fhir:title [ fhir:v "What is in this leaflet" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "What is in this leaflet" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What Genvoya is and what it is used for</li><li>What you need to know before you take Genvoya</li><li>How to take Genvoya</li><li>Possible side effects</li><li>How to store Genvoya</li><li>Contents of the pack and other information</li></ol></div>" ] ] [ fhir:title [ fhir:v "1. What genvoya is and what it is used for" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "1. What genvoya is and what it is used for" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Genvoya contains four active substances:</p><ul><li>elvitegravir, an antiretroviral medicine known as an integrase inhibitor</li><li>cobicistat, a booster (enhancer) of the effects of elvitegravir</li><li>emtricitabine, an antiretroviral medicine known as a nucleoside reverse transcriptase inhibitor (NRTI)</li><li>tenofovir alafenamide, an antiretroviral medicine known as a nucleotide reverse transcriptase inhibitor (NtRTI)</li></ul><p>Genvoya is a single tablet for the treatment of human immunodeficiency virus 1 (HIV-1) infection in adults, adolescents and children 2 years of age and older, who weigh at least 14 kg.</p><p>Genvoya reduces the amount of HIV in your body. This will improve your immune system and reduce the risk of developing illnesses linked to HIV infection.</p></div>" ] ] [ fhir:title [ fhir:v "2. What you need to know before you take genvoya" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "2. What you need to know before you take genvoya" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Do not take Genvoya</p><ul><li><p>If you are allergic to elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide or any of the other ingredients of this medicine (listed in section 6 of this leaflet).</p></li><li><p>If you are taking one of these medicines:</p></li></ul><ul><li><p>alfuzosin (used to treat an enlarged prostate gland)</p></li><li><p>dabigatran (used to prevent and treat blood clots)</p></li><li><p>amiodarone, quinidine (used to correct irregular heartbeats)</p></li><li><p>carbamazepine, phenobarbital, phenytoin (used to prevent seizures)</p></li><li><p>rifampicin (used to prevent and treat tuberculosis and other infections)</p></li><li><p>dihydroergotamine, ergometrine, ergotamine (used to treat migraine headache)</p></li><li><p>cisapride (used to relieve certain stomach problems)</p></li><li><p>St. John s wort (Hypericum perforatum, a herbal remedy used for depression and anxiety) or products that contain it</p></li><li><p>lomitapide, lovastatin, simvastatin (used to lower blood cholesterol)</p></li><li><p>lurasidone, pimozide (used to treat abnormal thoughts or feelings)</p></li><li><p>sildenafil (when used to treat pulmonary arterial hypertension a lung disease that makes breathing difficult)</p></li><li><p>orally administered midazolam, triazolam (used to help you sleep and/or relieve anxiety)</p><p>If any of these applies to you, do not take Genvoya and tell your doctor immediately.</p></li></ul><p>Warnings and precautions</p><p>You must remain under the care of your doctor while taking Genvoya.</p><p>This medicine is not a cure for HIV infection. While taking Genvoya you may still develop infections or other illnesses associated with HIV infection.</p><p>Talk to your doctor before taking Genvoya:</p><ul><li>If you have liver problems or a history of liver disease, including hepatitis. Patients with liver disease including chronic hepatitis B or C, who are treated with antiretrovirals, have a higher risk of severe and potentially fatal liver complications. If you have hepatitis B infection, your doctor will carefully consider the best treatment regimen for you.</li></ul><p>If you have hepatitis B infection, liver problems may become worse after you stop taking Genvoya. It is important not to stop taking Genvoya without talking to your doctor: see section 3, Do not stop taking Genvoya.</p><ul><li>If you have had kidney disease or if tests have shown problems with your kidneys. Your doctor may order blood tests to monitor how your kidneys work when starting and during treatment with Genvoya.</li></ul><p>While you are taking Genvoya</p><p>Once you start taking Genvoya, look out for:</p><ul><li><p>Signs of inflammation or infection</p></li><li><p>Joint pain, stiffness or bone problems</p><p>If you notice any of these symptoms, tell your doctor immediately. For more information see section 4, Possible side effects.</p></li></ul><p>There is a possibility that you may experience kidney problems when taking Genvoya over a long period of time (see Warnings and precautions).</p><p>Children and adolescents</p><p>Do not give this medicine to children under 2 years of age, or weighing less than 14 kg regardless of age. The use of Genvoya in children under 2 years of age, or weighing less than 14 kg has not yet been studied.</p><p>Other medicines and Genvoya</p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Genvoya may interact with other medicines. As a result, the amounts of Genvoya or other medicines in your blood may be affected. This may stop your medicines from working properly, or may make any side effects worse. In some cases, your doctor may need to adjust your dose or check your blood levels.</p><p>Medicines that must never be taken with Genvoya:</p><ul><li>alfuzosin (used to treat an enlarged prostate gland)</li><li>amiodarone, quinidine (used to correct irregular heartbeats)</li><li>carbamazepine, phenobarbital, phenytoin (used to prevent seizures)</li><li>dabigatran (used to prevent and treat blood clots)</li><li>rifampicin (used to prevent and treat tuberculosis and other infections)</li><li>dihydroergotamine, ergometrine, ergotamine (used to treat migraine headache)</li><li>cisapride (used to relieve certain stomach problems)</li><li>St. John s wort (Hypericum perforatum, a herbal remedy used for depression and anxiety) or products that contain it</li><li>lomitapide, lovastatin, simvastatin (used to lower blood cholesterol)</li><li>lurasidone, pimozide (used to treat abnormal thoughts or feelings)</li><li>sildenafil (when used to treat pulmonary arterial hypertension a lung disease that makes breathing difficult)</li><li>orally administered midazolam, triazolam (used to help you sleep and/or relieve anxiety) If you are taking any of these medicines, do not take Genvoya and tell your doctor immediately.</li></ul><p>Medicines used in treating hepatitis B infection:</p><p>You should not take Genvoya with medicines containing:</p><ul><li><p>tenofovir alafenamide</p></li><li><p>tenofovir disoproxil</p></li><li><p>lamivudine</p></li><li><p>adefovir dipivoxil</p><p>Tell your doctor if you are taking any of these medicines.</p></li></ul><p>Other types of medicine: Talk to your doctor if you are taking:</p><ul><li>antifungals, used to treat fungal infections, such as:</li></ul><ul><li>ketoconazole, itraconazole, voriconazole, posaconazole and fluconazole</li></ul><ul><li>antibiotics, used to treat bacterial infections including tuberculosis, containing:</li></ul><ul><li>rifabutin, clarithromycin and telithromycin</li></ul><ul><li>antidepressants, used to treat depression:</li></ul><ul><li>medicines containing trazodone or escitalopram</li></ul><ul><li>sedatives and hypnotics, used to treat anxiety:</li></ul><ul><li>buspirone, clorazepate, diazepam, estazolam, flurazepam, zolpidem and lorazepam</li></ul><ul><li>immunosuppressants, used to control your body s immune response after a transplant, such as:</li></ul><ul><li>ciclosporin, sirolimus and tacrolimus</li></ul><ul><li>corticosteroids including:</li></ul><ul><li>betamethasone, budesonide, fluticasone, mometasone, prednisone, triamcinolone. These medicines are used to treat allergies, asthma, inflammatory bowel diseases, inflammatory conditions of the skin, eyes, joints and muscles and other inflammatory conditions. These medicines are generally taken orally, inhaled, injected or applied to the skin or eye. If alternatives cannot be used, its use should only take place after medical evaluation and under close monitoring by your doctor for corticosteroid side effects.</li></ul><ul><li>medicines used to treat diabetes:</li></ul><ul><li>metformin</li></ul><ul><li>contraceptive pill, used to prevent pregnancy</li><li>erectile dysfunction medicines, used to treat impotence, such as:</li></ul><ul><li>sildenafil, tadalafil and vardenafil</li></ul><ul><li>heart medicines, such as:</li></ul><ul><li>digoxin, disopyramide, flecainide, lidocaine (injectable), mexiletine, propafenone, metoprolol, timolol, amlodipine, diltiazem, felodipine, nicardipine, nifedipine and verapamil</li></ul><ul><li>medicines used to treat pulmonary arterial hypertension:</li></ul><ul><li>bosentan and tadalafil</li></ul><ul><li>anticoagulants, used to prevent and treat blood clots, such as:</li></ul><ul><li>apixaban, edoxaban, rivaroxaban and warfarin</li></ul><ul><li>bronchodilators, used to treat asthma and other lung-related problems:</li></ul><ul><li>salmeterol</li></ul><ul><li>cholesterol lowering medicines, such as:</li></ul><ul><li>atorvastatin and pitavastatin</li></ul><ul><li>medicines used to treat gout:</li></ul><ul><li>colchicine</li></ul><ul><li>antiplatelets, used to reduce the risk of blood clots such as:</li></ul><ul><li>clopidogrel</li></ul><ul><li>medicines or oral supplements containing minerals (such as magnesium, aluminium, calcium, iron, zinc), such as:</li></ul><ul><li><p>mineral supplements, vitamins (including multivitamins), antacids and laxatives If you are taking medicines, oral supplements, antacids or laxatives containing minerals (such as magnesium, aluminium, calcium, iron, zinc), take them at least 4 hours before or at least 4 hours after Genvoya.</p><p>Tell your doctor if you are taking these or any other medicines. Do not stop your treatment without contacting your doctor.</p></li></ul><p>Pregnancy and breast-feeding</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><ul><li>Tell your doctor immediately if you are pregnant, think you may be pregnant or are planning to have a baby. Pregnant women should not take Genvoya. The amount of this medicine in your blood may decrease during pregnancy which may stop it from working properly.</li><li>Use effective contraception while taking Genvoya.</li><li>Do not breast-feed during treatment with Genvoya. This is because some of the active substances in this medicine pass into human breast milk. Breast-feeding is not recommended in women living with HIV because HIV infection can be passed on to the baby in breast milk. If you are breast-feeding, or thinking about breast-feeding, you should discuss it with your doctor as soon as possible.</li></ul><p>Driving and using machines</p><p>Genvoya can cause dizziness. If you feel dizzy when taking Genvoya, do not drive or ride a bicycle and do not use any tools or machines.</p><p>Genvoya contains sodium</p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium- free .</p><p>Genvoya contains lactose</p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>If any of these applies to you, talk to your doctor before taking Genvoya.</p></div>" ] ] [ fhir:title [ fhir:v "3. How to take genvoya" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "3. How to take genvoya" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>There are two strengths of Genvoya tablets. Your doctor will prescribe the appropriate tablet for your age and weight.</p><p>The recommended dose is:</p><p>Adults, adolescents and children who weigh at least 25 kg: one tablet each day with food (one 150 mg/150 mg/200 mg/10 mg tablet)</p><p>Children 2 years of age and older, who weigh at least 14 kg but less than 25 kg: one tablet each day with food (one 90 mg/90 mg/120 mg/6 mg tablet)</p><p>Due to the bitter taste, it is recommended not to chew or crush the tablet.</p><p>If you have difficulty swallowing the tablet whole, you can split it in half. Take both halves of the tablet one after the other to get the full dose. Do not store the split tablet. The score line on the 90 mg/90 mg/120 mg/6 mg tablet is only there to help you break the tablet if your child has difficulty swallowing it whole.</p><p>Always take the dose recommended by your doctor. This is to make sure that your medicine is fully effective, and to reduce the risk of developing resistance to the treatment. Do not change the dose unless your doctor tells you to.</p><p>Do not take antacids or multivitamins at the same time as Genvoya. If you are taking medicines, oral supplements, antacids or laxatives containing minerals (such as magnesium, aluminium, calcium, iron, zinc), take them at least 4 hours before or at least 4 hours after Genvoya.</p><p>If you are on dialysis, take your daily dose of Genvoya following completion of dialysis.</p><p>If you take more Genvoya than you should</p><p>If you accidentally take more than the recommended dose of Genvoya you may be at increased risk of experiencing possible side effects with this medicine (see section 4, Possible side effects).</p><p>Contact your doctor or nearest emergency department immediately for advice. Keep the tablet bottle with you so that you can easily describe what you have taken.</p><p>If you forget to take Genvoya</p><p>It is important not to miss a dose of Genvoya.</p><p>If you do miss a dose:</p><ul><li>If you notice within 18 hours of the time you usually take Genvoya, you must take the tablet as soon as possible. Always take the tablet with food. Then take the next dose as usual.</li><li>If you notice 18 hours or more after the time you usually take Genvoya, then do not take the missed dose. Wait and take the next dose, with food, at your usual time.</li></ul><p>If you vomit less than 1 hour after taking Genvoya, take another tablet with food.</p><p>Do not stop taking Genvoya</p><p>Do not stop taking Genvoya without talking to your doctor. Stopping Genvoya can seriously affect your response to future treatment. If Genvoya is stopped for any reason, speak to your doctor before you restart taking Genvoya tablets.</p><p>When your supply of Genvoya starts to run low, get more from your doctor or pharmacist. This is very important because the amount of virus may start to increase if the medicine is stopped for even a short time. The disease may then become harder to treat.</p><p>If you have both HIV infection and hepatitis B, it is especially important not to stop your Genvoya treatment without talking to your doctor first. You may require blood tests for several months after stopping treatment. In some patients with advanced liver disease or cirrhosis, stopping treatment is not recommended as this may lead to worsening of your hepatitis, which may be life-threatening.</p><p>Tell your doctor immediately about new or unusual symptoms after you stop treatment, particularly symptoms you associate with hepatitis B infection.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>" ] ] [ fhir:title [ fhir:v "4. Possible side effects" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "4. Possible side effects" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>Possible serious side effects: tell a doctor immediately</p><ul><li><p>Any signs of inflammation or infection. In some patients with advanced HIV infection (AIDS) and a history of opportunistic infections (infections that occur in people with a weak immune system), signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started. It is thought that these symptoms are due to an improvement in the body s immune response, enabling the body to fight infections that may have been present with no obvious symptoms.</p></li><li><p>Autoimmune disorders, when the immune system attacks healthy body tissue, may also occur after you start taking medicines for HIV infection. Autoimmune disorders may occur many months after the start of treatment. Look out for any symptoms of infection or other symptoms such as:</p></li></ul><ul><li><p>muscle weakness</p></li><li><p>weakness beginning in the hands and feet and moving up towards the trunk of the body</p></li><li><p>palpitations, tremor or hyperactivity.</p><p>If you notice the side effects described above, tell your doctor immediately.</p></li></ul><p>Very common side effects (may affect more than 1 in 10 people)</p><ul><li>feeling sick (nausea)</li></ul><p>Common side effects (may affect up to 1 in 10 people)</p><ul><li>abnormal dreams</li><li>headache</li><li>dizziness</li><li>diarrhoea</li><li>vomiting</li><li>stomach pain</li><li>wind (flatulence)</li><li>rash</li><li>tiredness (fatigue)</li></ul><p>Uncommon side effects (may affect up to 1 in 100 people)</p><ul><li><p>low red blood cell count (anaemia)</p></li><li><p>suicidal thoughts and suicide attempt (in patients who have had depression or mental health problems before), depression</p></li><li><p>problems with digestion resulting in discomfort after meals (dyspepsia)</p></li><li><p>swelling of the face, lips, tongue or throat (angioedema)</p></li><li><p>itching (pruritus)</p></li><li><p>hives (urticaria)</p><p>If any of the side effects get serious tell your doctor.</p></li></ul><p>Other effects that may be seen during HIV treatment</p><p>The frequency of the following side effects is not known (frequency cannot be estimated from the available data).</p><ul><li>Bone problems. Some patients taking combination antiretroviral medicines such as Genvoya may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). Taking this type of medicine for a long time, taking corticosteroids, drinking alcohol, having a very weak immune system, and being overweight, may be some of the many risk factors for developing this disease. Signs of osteonecrosis are:</li></ul><ul><li>joint stiffness</li><li>joint aches and pains (especially of the hip, knee and shoulder)</li><li>difficulty with movement If you notice any of these symptoms tell your doctor.</li></ul><p>During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. This is partly linked to restored health and life style, and in the case of blood lipids sometimes to the HIV medicines themselves. Your doctor will test for these changes.</p><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>" ] ] [ fhir:title [ fhir:v "5. How to store genvoya" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "5. How to store genvoya" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and bottle after {EXP}.<br/>The expiry date refers to the last day of that month. Store in the original package in order to protect from moisture. Keep the bottle tightly closed.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>" ] ] [ fhir:title [ fhir:v "6. Contents of the pack and other information" ] ; fhir:code [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi/"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000155538" ] ] ) ; fhir:text [ fhir:v "6. Contents of the pack and other information" ] ] ; fhir:text [ fhir:status [ fhir:v "additional" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What Genvoya contains</p><p>The active substances are elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide.</p><ul><li>Each Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablet contains 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine and tenofovir alafenamide fumarate equivalent to 10 mg of tenofovir alafenamide.</li><li>Each Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablet contains 90 mg of elvitegravir, 90 mg of cobicistat, 120 mg of emtricitabine and tenofovir alafenamide fumarate equivalent to 6 mg of tenofovir alafenamide.</li></ul><p>The other ingredients are</p><p>Tablet core: Lactose (as monohydrate), microcrystalline cellulose (E460), croscarmellose sodium, hydroxypropyl cellulose (E463), silicon dioxide (E551), sodium lauryl sulfate, magnesium stearate.</p><p>Film-coating: Polyvinyl alcohol (E1203), titanium dioxide (E171), polyethylene glycol (E1521), talc (E553b), iron oxide yellow (E172), indigo carmine aluminium lake (E132 - 150 mg/150 mg/200 mg/10 mg tablet only), iron oxide black (E172 - 90 mg/90 mg/120 mg/6 mg tablet only).</p><p>What Genvoya looks like and contents of the pack</p><p>Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets are green, capsule-shaped tablets, debossed on one side with GSI and the number 510 on the other side of the tablet.</p><p>Genvoya 90 mg/90 mg/120 mg/6 mg film-coated tablets are green, capsule-shaped tablets, debossed on one side with GSI and scored on the other side of the tablet.</p><p>Genvoya comes in bottles of 30 tablets (with a silica gel desiccant that must be kept in the bottle to help protect your tablets). The silica gel desiccant is contained in a separate sachet or canister and should not be swallowed.</p><p>The following pack sizes are available: outer cartons containing 1 bottle of 30 film-coated tablets and outer cartons containing 90 (3 bottles of 30) film-coated tablets. Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder Gilead Sciences Ireland UC Carrigtohill County Cork, T45 DPIreland</p><p>Manufacturer Gilead Sciences Ireland UC IDA Business & Technology Park Carrigtohill County Cork Ireland For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien Gilead Sciences Belgium SRL-BV T l/Tel: + 32 (0) 24 01 35 Lietuva Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8<br/>Gilead Sciences Ireland UC .: + 353 (0) 1 686 1Luxembourg/Luxemburg Gilead Sciences Belgium SRL-BV T l/Tel: + 32 (0) 24 01 35 esk republika Gilead Sciences s.r.o. Tel: + 420 910 871 Magyarorsz g Gilead Sciences Ireland UC Tel.: + 353 (0) 1 686 1Danmark Gilead Sciences Sweden AB Tlf: + 46 (0) 8 5057 1Malta Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1Deutschland Gilead Sciences GmbH Tel: + 49 (0) 89 899890-0</p><p>Nederland Gilead Sciences Netherlands B.V. Tel: + 31 (0) 20 718 36 Eesti Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8Norge Gilead Sciences Sweden AB Tlf: + 46 (0) 8 5057 1<br/>Gilead Sciences . . : + 30 210 8930 sterreich Gilead Sciences GesmbH Tel: + 43 1 260 Espa a Gilead Sciences, S.L. Tel: + 34 91 378 98 Polska Gilead Sciences Poland Sp. z o.o. Tel.: + 48 22 262 8France Gilead Sciences T l: + 33 (0) 1 46 09 41 Portugal Gilead Sciences, Lda. Tel: + 351 21 7928Hrvatska Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1Rom nia Gilead Sciences (GSR) S.R.L. Tel: + 40 31 631 18 Ireland Gilead Sciences Ireland UC Tel: + 353 (0) 214 825 Slovenija Gilead Sciences Ireland UC Tel: + 353 (0) 1 686 1 sland Gilead Sciences Sweden AB S mi: + 46 (0) 8 5057 1Slovensk republika Gilead Sciences Slovakia s.r.o. Tel: + 421 232 121 Italia Gilead Sciences S.r.l. Tel: + 39 02 439Suomi/Finland Gilead Sciences Sweden AB Puh/Tel: + 46 (0) 8 5057 1<br/>Gilead Sciences . . : + 30 210 8930 Sverige Gilead Sciences Sweden AB Tel: + 46 (0) 8 5057 1Latvija Gilead Sciences Poland Sp. z o.o. Tel: + 48 22 262 8United Kingdom (Northern Ireland) Gilead Sciences Ireland UC<br/>Tel: + 44 (0) 8000 113 This leaflet was last revised in</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>" ] ] ) ] ) . # <MedicinalProductDefinition/mp9e5179bf4e803289b510a39f498792d0> a fhir:MedicinalProductDefinition ; fhir:id [ fhir:v "mp9e5179bf4e803289b510a39f498792d0"] ; # fhir:meta [ ( fhir:profile [ fhir:v "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"^^xsd:anyURI ; fhir:link <http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi> ] ) ] ; # fhir:text [ fhir:status [ fhir:v "generated" ] ; fhir:div "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mp9e5179bf4e803289b510a39f498792d0\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mp9e5179bf4e803289b510a39f498792d0</b></p><a name=\"mp9e5179bf4e803289b510a39f498792d0\"> </a><a name=\"hcmp9e5179bf4e803289b510a39f498792d0\"> </a><a name=\"mp9e5179bf4e803289b510a39f498792d0-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/15/1061/001</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>" ] ; # fhir:identifier ( [ fhir:system [ fhir:v "http://ema.europa.eu/identifier"^^xsd:anyURI ] ; fhir:value [ fhir:v "EU/1/15/1061/001" ] ] ) ; # fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/medicinal-product-type"^^xsd:anyURI ] ; fhir:code [ fhir:v "MedicinalProduct" ] ; fhir:display [ fhir:v "Medicinal Product" ] ] ) ] ; # fhir:domain [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/medicinal-product-domain"^^xsd:anyURI ] ; fhir:code [ fhir:v "Human" ] ; fhir:display [ fhir:v "Human use" ] ] ) ] ; # fhir:status [ ( fhir:coding [ fhir:system [ fhir:v "http://hl7.org/fhir/publication-status"^^xsd:anyURI ] ; fhir:code [ fhir:v "active" ] ; fhir:display [ fhir:v "active" ] ] ) ] ; # fhir:legalStatusOfSupply [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/rmswi"^^xsd:anyURI ] ; fhir:code [ fhir:v "100000072084" ] ; fhir:display [ fhir:v "Medicinal product subject to medical prescription" ] ] ) ] ; # fhir:name ( [ fhir:productName [ fhir:v "Genvoya 150 mg/150 mg/200 mg/10 mg film-coated tablets" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000001" ] ; fhir:display [ fhir:v "Full name" ] ] ) ] ; ( fhir:part [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000002" ] ; fhir:display [ fhir:v "Invented name part" ] ] ) ] ] [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000003" ] ; fhir:display [ fhir:v "Scientific name part" ] ] ) ] ] [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000004" ] ; fhir:display [ fhir:v "Strength part" ] ] ) ] ] [ fhir:part [ fhir:v "nan" ] ; fhir:type [ ( fhir:coding [ fhir:system [ fhir:v "https://spor.ema.europa.eu/lists/220000000000"^^xsd:anyURI ] ; fhir:code [ fhir:v "220000000005" ] ; fhir:display [ fhir:v "Pharmaceutical dose form part" ] ] ) ] ] ) ; ( fhir:usage [ fhir:country [ ( fhir:coding [ fhir:system [ fhir:v "urn:iso:std:iso:3166"^^xsd:anyURI ] ; fhir:code [ fhir:v "EU" ] ; fhir:display [ fhir:v "EU" ] ] ) ] ; fhir:jurisdiction [ ( fhir:coding [ fhir:system [ fhir:v "urn:iso:std:iso:3166"^^xsd:anyURI ] ; fhir:code [ fhir:v "EU" ] ; fhir:display [ fhir:v "EU" ] ] ) ] ; fhir:language [ ( fhir:coding [ fhir:system [ fhir:v "urn:ietf:bcp:47"^^xsd:anyURI ] ; fhir:code [ fhir:v "en" ] ; fhir:display [ fhir:v "en" ] ] ) ] ] ) ] ) . #
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
